Nuvation Bio is trading at $4.45, down 5.43%, with broader market weakness the likeliest explanation; no company-specific negative catalyst was confirmed.
- Biotech shares were under pressure: IBB was down 1% premarket, while supplied sector context reported XBI down 2.08%.
- The latest company announcement scheduled third-quarter results for November 4.
- Risk-off sentiment, rising oil prices, and geopolitical concerns weighed on markets October 23; volume data was unavailable.